These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20981524)

  • 21. Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening.
    Vrontaki E; Melagraki G; Mavromoustakos T; Afantitis A
    J Enzyme Inhib Med Chem; 2016; 31(1):38-52. PubMed ID: 26060939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
    Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
    Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
    Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
    J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
    Alexandre FR; Badaroux E; Bilello JP; Bot S; Bouisset T; Brandt G; Cappelle S; Chapron C; Chaves D; Convard T; Counor C; Da Costa D; Dukhan D; Gay M; Gosselin G; Griffon JF; Gupta K; Hernandez-Santiago B; La Colla M; Lioure MP; Milhau J; Paparin JL; Peyronnet J; Parsy C; Pierra Rouvière C; Rahali H; Rahali R; Salanson A; Seifer M; Serra I; Standring D; Surleraux D; Dousson CB
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4323-4330. PubMed ID: 28835346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.
    Yang H; Hendricks RT; Arora N; Nitzan D; Yee C; Lucas MC; Yang Y; Fung A; Rajyaguru S; Harris SF; Leveque VJ; Hang JQ; Pogam SL; Reuter D; Tavares GA
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4614-9. PubMed ID: 20584604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening.
    Li J; Liu X; Li S; Wang Y; Zhou N; Luo C; Luo X; Zheng M; Jiang H; Chen K
    Int J Mol Sci; 2013 Nov; 14(11):22845-56. PubMed ID: 24264035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.
    Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL
    Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
    LaPlante SR; Bös M; Brochu C; Chabot C; Coulombe R; Gillard JR; Jakalian A; Poirier M; Rancourt J; Stammers T; Thavonekham B; Beaulieu PL; Kukolj G; Tsantrizos YS
    J Med Chem; 2014 Mar; 57(5):1845-54. PubMed ID: 24159919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library.
    Ma DL; Chan DS; Wei G; Zhong HJ; Yang H; Leung LT; Gullen EA; Chiu P; Cheng YC; Leung CH
    Chem Commun (Camb); 2014 Nov; 50(90):13885-8. PubMed ID: 25225654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors.
    Barnes-Seeman D; Boiselle C; Capacci-Daniel C; Chopra R; Hoffmaster K; Jones CT; Kato M; Lin K; Ma S; Pan G; Shu L; Wang J; Whiteman L; Xu M; Zheng R; Fu J
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3979-85. PubMed ID: 24986660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based and property-compliant library design of 11β-HSD1 adamantyl amide inhibitors.
    Paderes GD; Dress K; Huang B; Elleraas J; Rejto PA; Pauly T
    Methods Mol Biol; 2011; 685():191-215. PubMed ID: 20981525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.
    Brvar M; Perdih A; Renko M; Anderluh G; Turk D; Solmajer T
    J Med Chem; 2012 Jul; 55(14):6413-26. PubMed ID: 22731783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.
    Gentles RG; Sheriff S; Beno BR; Wan C; Kish K; Ding M; Zheng X; Chupak L; Poss MA; Witmer MR; Morin P; Wang YK; Rigat K; Lemm J; Voss S; Liu M; Pelosi L; Roberts SB; Gao M; Kadow JF
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2212-5. PubMed ID: 21441029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.
    de Vicente J; Hendricks RT; Smith DB; Fell JB; Fischer J; Spencer SR; Stengel PJ; Mohr P; Robinson JE; Blake JF; Hilgenkamp RK; Yee C; Adjabeng G; Elworthy TR; Li J; Wang B; Bamberg JT; Harris SF; Wong A; Leveque VJ; Najera I; Le Pogam S; Rajyaguru S; Ao-Ieong G; Alexandrova L; Larrabee S; Brandl M; Briggs A; Sukhtankar S; Farrell R
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5652-6. PubMed ID: 19709881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
    Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
    J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.
    Stammers TA; Coulombe R; Duplessis M; Fazal G; Gagnon A; Garneau M; Goulet S; Jakalian A; LaPlante S; Rancourt J; Thavonekham B; Wernic D; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6879-85. PubMed ID: 24176401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.